Genzyme Takes Shot At Watson Over Renvela ANDA
Genzyme Corp. has launched the latest in a string of suits over its kidney disease treatments, accusing Watson Laboratories Inc. of infringing a patent for Renvela through an abbreviated new drug...To view the full article, register now.
Already a subscriber? Click here to view full article